title: Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
abstract: The targeted terminal complement inhibitor eculizumab (Soliris) reduces intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as stabilizing hemoglobin levels, improving fatigue and health-related quality of life, and reducing the requirement for packed red cell transfusions. Eculizumab is generally well tolerated in patients with PNH, although the risk of Neisseria meningitidis infection is increased with eculizumab, meaning that patients must be vaccinated.
authors.affiliation: Adis, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Keating
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Lyseng-Williamson
authors.forename: Kate
authors.initials: K
authors.lastname: McKeage
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003182:Complement C5 / Q000037:antagonists & inhibitors; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy*; D006461:Hemolysis / Q000187:drug effects; D006801:Humans
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003182:Complement C5; C481642:eculizumab